PDT FOR BLADDER CANCER
WHOLE-BLADDER TREATMENT FOR BCG-REFRACTORY CIS
When BCG immunotherapy fails to control bladder carcinoma in situ, cystectomy โ removal of the bladder โ is the standard recommendation. For patients who wish to preserve their bladder, whole-bladder PDT offers an evidence-based alternative with complete response rates that allow bladder preservation in selected patients.
analyticsAt a Glance
- check_circleBCG-refractory CIS: cystectomy is standard; PDT is the most evidence-based bladder-preserving alternative
- check_circleWhole-bladder illumination via intracystic fibre during cystoscopy โ treats entire bladder mucosa simultaneously
- check_circleComplete response 40โ60% in BCG-refractory CIS allowing bladder preservation
- check_circleALA (5-ALA) intravesical instillation and Photofrin IV both used in published series
The BCG-Refractory CIS Problem
Bladder carcinoma in situ (CIS) is a high-risk, non-muscle-invasive bladder cancer that has a strong tendency to progress to muscle-invasive disease. BCG intravesical immunotherapy is the standard treatment โ achieving complete response in 60โ80% of patients. But 20โ40% of CIS patients either never respond to BCG or recur after initial response. This "BCG-refractory" group faces a difficult decision.
โRadical cystectomy cures most BCG-refractory CIS โ but at the cost of the bladder and the quality of life that comes with it. For many patients, the prospect of urinary diversion drives a strong desire for a bladder-preserving option.โ
The Standard: Radical Cystectomy
Radical cystectomy โ complete bladder removal with urinary diversion โ is the oncologically safe standard for BCG-refractory high-risk non-muscle-invasive bladder cancer. Cancer-specific survival rates are excellent. But the procedure carries substantial morbidity: ostomy formation, sexual dysfunction, changes in urinary function, and significant recovery time. Many patients, particularly older individuals with comorbidities, seek alternatives.
Why PDT Is Well-Suited to Bladder CIS
CIS is a flat, diffuse mucosal disease โ the ideal setting for PDT's field treatment capability. Unlike focal tumours where precise excision or ablation is needed, CIS requires treatment of the entire bladder mucosa. Whole-bladder PDT illuminates the full bladder surface simultaneously via a light diffuser โ perfectly matching the diffuse nature of CIS.
Two Photosensitiser Approaches for Bladder PDT
Bladder PDT uses two distinct photosensitiser delivery approaches โ systemic Photofrin (IV) and intravesical ALA instillation. Each has advantages that drive their use in different clinical contexts.
Photofrin (IV) โ Systemic Approach
Photofrin is administered intravenously โ the same protocol as for oesophageal or endobronchial PDT (2 mg/kg, 40โ50h before light). The drug accumulates in bladder mucosal cells and is activated by whole-bladder light delivery during cystoscopy. The major disadvantage: full-body photosensitivity for 4โ6 weeks. Most of the larger published bladder PDT series use Photofrin.
ALA (5-ALA) โ Intravesical Instillation
5-ALA solution is instilled directly into the bladder via a urinary catheter โ held for 1โ2 hours. The drug is converted to PpIX preferentially in the bladder mucosal cells and is then activated by whole-bladder light delivery. Key advantage: intravesical instillation limits systemic absorption, producing minimal systemic photosensitivity (24โ48 hours max). This approach is increasingly preferred for bladder PDT.
Whole-Bladder PDT Procedure
The procedure for intravesical ALA-based whole-bladder PDT โ the most commonly used contemporary approach.
- 1
Step 1: Pre-Treatment Bladder Assessment
Cystoscopy and random biopsies confirm CIS distribution and absence of muscle-invasive disease. Urine cytology, CT urogram to exclude upper urinary tract disease. Haematuria controlled before procedure.
- 2
Step 2: Intravesical ALA Instillation
5-ALA solution (typically 50 mM in saline or 1.5g in 50 mL) instilled into the bladder via urinary catheter. Catheter clamped for 1โ2 hours. Patient rotates position during instillation to ensure complete mucosal contact. Minimal systemic absorption โ photosensitivity limited to 24โ48 hours.
- 3
Step 3: Cystoscopy Under General Anaesthesia
Spinal or general anaesthesia. Rigid or flexible cystoscopy. Bladder irrigated to remove residual ALA. Diffuser fibre (spherical intravesical light diffuser, typically 4โ6 cm diameter) introduced through the cystoscope into the bladder to achieve whole-bladder illumination.
- 4
Step 4: Whole-Bladder Light Delivery
Red laser at 630โ635 nm delivered through the spherical diffuser. Light dose: 15โ30 J/cmยฒ delivered over 15โ45 minutes. The diffuser provides uniform isotropic illumination of the entire bladder wall. Light dose is calculated based on bladder capacity to ensure uniform irradiance.
- 5
Step 5: Recovery and Discharge
Most patients discharged same day or after one overnight stay. Urinary discomfort (dysuria, frequency) for 3โ7 days from bladder mucosal inflammation. Haematuria (blood in urine) common for several days โ expected. Hydration and analgesics as needed.
- 6
Step 6: Cystoscopy + Biopsy Response Assessment
Repeat cystoscopy with biopsies at 3 months confirms complete response (no CIS on biopsy) or persistent disease. Complete responders continue surveillance cystoscopy every 3 months for 2 years. Persistent disease requires further decision: repeat PDT or cystectomy.
Outcomes Data: PDT for BCG-Refractory Bladder CIS
Published complete response rates and bladder preservation outcomes from major bladder PDT series.
Complete Response at 3 Months โ BCG-Refractory CIS
Complete response defined as negative cystoscopy and negative biopsies at 3 months. Photofrin series and ALA series show comparable response rates.
- Intravesical ALA-PDT40โ60%
- Systemic Photofrin-PDT40โ65%
- BCG Retreatment (refractory patients)15โ30%
Bladder Preservation Rate at 2 Years (Complete Responders)
Among patients achieving complete response at 3 months, proportion retaining their bladder at 2-year follow-up.
- Bladder Intact at 2 Years (CR patients)55โ70%
- Cystectomy Required by 2 Years30โ45%
Explore the PDT Knowledge Base
Related PDT topics and resources.
- What Is Photodynamic Therapy and How Does It Work?
- ALA and Methyl-ALA: Topical Photosensitisers for Skin Cancer PDT
- PDT Photosensitivity: The Complete Protection Guide
- Photodynamic Therapy โ Full Treatment Page
- Bladder Cancer โ Condition Page
- HIVEC โ Hyperthermic Intravesical Chemotherapy for Bladder Cancer
Frequently Asked Questions
Common questions about PDT for bladder cancer.
About the Treatment
Can I avoid cystectomy with bladder PDT?
PDT offers the possibility of bladder preservation in BCG-refractory CIS โ complete response at 3 months in 40โ60% of patients. Of complete responders, approximately 55โ70% still retain their bladder at 2 years. This means roughly 25โ40% of all treated patients achieve durable bladder preservation at 2 years. The remainder ultimately need cystectomy. PDT gives a meaningful chance of bladder preservation but is not a guaranteed alternative. The decision to pursue PDT vs proceed to cystectomy involves the specific risk tolerance and quality-of-life priorities of the individual patient.
How does intravesical ALA compare to IV Photofrin for bladder PDT?
Intravesical ALA instillation is increasingly preferred because it confines the photosensitiser to the bladder, producing only 24โ48 hours of local photosensitivity rather than the 4โ6 weeks of full-body photosensitivity from Photofrin. Efficacy appears comparable in published series. Most contemporary bladder PDT programmes prefer intravesical ALA for this reason. However, published evidence is more extensive for Photofrin โ intravesical ALA bladder PDT data is from smaller series.
Access
Where can I access bladder PDT?
Whole-bladder PDT for BCG-refractory CIS is a specialised procedure available at a limited number of urologic oncology centres globally โ primarily in France, Japan, the Netherlands, and selected centres in China, India, and the US. The combination of cystoscopy expertise, PDT laser systems, and urologic oncology is not universally available. CancerFax identifies appropriate centres based on your specific case and coordinates pre-screening and logistics.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
BCG-Refractory Bladder CIS? PDT May Help You Keep Your Bladder.
Upload your cystoscopy reports, biopsy results, and BCG treatment history. Our urologic oncology team will assess whether whole-bladder PDT is appropriate and identify the most experienced centres.
For informational purposes only. Bladder cancer treatment decisions require evaluation by qualified urologic oncology specialists. Cystectomy remains the safest oncological option for BCG-refractory high-risk disease โ PDT is a selected alternative for appropriate patients.